엄현석 국립암센터 의사
엄현석 (嚴炫晳) 1965-
엄현석
VIAF ID: 33149841811902840081 (Personal)
Permalink: http://viaf.org/viaf/33149841811902840081
Preferred Forms
- 100 0 _ ‡a 엄현석
- 100 0 _ ‡a 엄현석 ‡c 국립암센터 의사
- 100 1 _ ‡a 엄현석 ‡g 嚴炫晳 ‡d 1965-
4xx's: Alternate Name Forms (11)
5xx's: Related Names (1)
- 510 2 _ ‡a 국립암센터
Works
Title | Sources |
---|---|
Comparison of spectra optia and amicus cell separators for autologous peripheral blood stem cell collection | |
Comprehensive Evaluation of the Revised International Staging System in Multiple Myeloma Patients Treated with Novel Agents as a Primary Therapy. | |
Consideration of aggressive therapeutic strategies for primary testicular lymphoma. | |
CTLA4-CD28 chimera gene modification of T cells enhances the therapeutic efficacy of donor lymphocyte infusion for hematological malignancy | |
Cyclosporine A in the treatment of a patient with immune thrombocytopenia accompanied by myelodysplastic syndrome and nephrotic syndrome | |
Detection of circulating lymphoma cells in patients with non-Hodgkin lymphoma using MAGE-A3 gene expression in peripheral blood | |
Development of an Automated Image Analyzer for Microvessel Density Measurement in Bone Marrow Biopsies | |
The different roles of molecular classification according to upfront autologous stem cell transplantation in advanced-stage diffuse large B cell lymphoma patients with elevated serum lactate dehydrogenase | |
Early response to bortezomib combined chemotherapy can help predict survival in patients with multiple myeloma who are ineligible for stem cell transplantation. | |
Efficacy of Brentuximab Vedotin in Relapsed or Refractory High-CD30-Expressing Non-Hodgkin Lymphomas: Results of a Multicenter, Open-Labeled Phase II Trial | |
Efficacy of eculizumab in paroxysmal nocturnal hemoglobinuria patients with or without aplastic anemia: prospective study of a Korean PNH cohort | |
Escalated daunorubicin dosing as an induction treatment for Philadelphia-negative adult acute lymphoblastic leukemia. | |
Expression of myeloid antigen in neoplastic plasma cells is related to adverse prognosis in patients with multiple myeloma | |
Frontline rituximab, cyclophosphamide, doxorubicin, and prednisone with bortezomib (VR-CAP) or vincristine (R-CHOP) for non-GCB DLBCL. | |
The host environment regulates the function of CD8+ graft-versus-host-reactive effector cells. | |
Host MHC class II+ antigen-presenting cells and CD4 cells are required for CD8-mediated graft-versus-leukemia responses following delayed donor leukocyte infusions | |
Identification of hypoxanthine as a urine marker for non-Hodgkin lymphoma by low-mass-ion profiling | |
Immune system | |
The impact of upfront versus sequential use of bortezomib among patients with newly diagnosed multiple myeloma (MM): a joint analysis of the Singapore MM Study Group and the Korean MM Working Party for the Asian myeloma network | |
Interleukin-10 Polymorphisms in Association with Prognosis in Patients with B-Cell Lymphoma Treated by R-CHOP. | |
Low-dose cisplatin converts the tumor microenvironment into a permissive state for HSVtk-induced antitumor immunity in HPV16-related tonsillar carcinoma | |
Lymphopenia is an important prognostic factor in peripheral T-cell lymphoma (NOS) treated with anthracycline-containing chemotherapy | |
Matched-pair analysis comparing the outcomes of primary breast and nodal diffuse large B-cell lymphoma in patients treated with rituximab plus chemotherapy | |
Multicenter analysis of treatment outcomes in adult patients with lymphoblastic lymphoma who received hyper-CVAD induction followed by hematopoietic stem cell transplantation. | |
Multicenter phase II study of bendamustine plus rituximab in patients with relapsed or refractory diffuse large B-cell lymphoma | |
Multiple myeloma in Korea: past, present, and future perspectives. Experience of the Korean Multiple Myeloma Working Party. | |
Mutational analysis of EZH2 codon 641 in non-Hodgkin lymphomas and leukemias | |
Nationwide Statistical Analysis of Lymphoid Malignancies in Korea | |
Neural stem cell transplant survival in brains of mice: assessing the effect of immunity and ischemia by using real-time bioluminescent imaging | |
Nilotinib combined with multiagent chemotherapy for newly diagnosed Philadelphia-positive acute lymphoblastic leukemia | |
Oncogenic NRF2 mutations in squamous cell carcinomas of oesophagus and skin | |
Phase 2 Study of an Intravenous Busulfan and Melphalan Conditioning Regimen for Autologous Stem Cell Transplantation in Patients with Multiple Myeloma (Kmm150). | |
Phase I Clinical Trial of 4-1BB-based Adoptive T-Cell Therapy for Epstein-Barr Virus (EBV)-positive Tumors | |
Phase I study of CKD-581, a pan-histone deacetylase inhibitor, in patients with lymphoma or multiple myeloma refractory to standard therapy. | |
Phase II trial of concurrent chemoradiotherapy with L-asparaginase and MIDLE chemotherapy for newly diagnosed stage I/II extranodal NK/T-cell lymphoma, nasal type (CISL-1008) | |
Plerixafor use for peripheral blood stem cell mobilization in Korea | |
Polymorphic Region-Specific Antibody for Evaluation of Affinity-Associated Profile of Chimeric Antigen Receptor | |
Pomalidomide, cyclophosphamide, and dexamethasone for elderly patients with relapsed and refractory multiple myeloma: A study of the Korean Multiple Myeloma Working Party (KMMWP-164 study) | |
Positive conversion of negative signaling of CTLA4 potentiates antitumor efficacy of adoptive T-cell therapy in murine tumor models. | |
Post-Transplantation Natural Killer Cell Count: A Predictor of Acute Graft-Versus-Host Disease and Survival Outcomes After Allogeneic Hematopoietic Stem Cell Transplantation. | |
Pralatrexate in patients with recurrent or refractory peripheral T-cell lymphomas: a multicenter retrospective analysis | |
The prognostic impact of inflammatory factors in patients with multiple myeloma treated with thalidomide in Korea | |
Prognostic role of the neutrophil-to-lymphocyte ratio in patients with primary central nervous system lymphoma | |
Quantitative analysis of tumor-specific BCL2 expression in DLBCL: refinement of prognostic relevance of BCL2 | |
R-CHOP chemoimmunotherapy followed by autologous transplantation for the treatment of diffuse large B-cell lymphoma | |
Radiation therapy for gastric mucosa-associated lymphoid tissue lymphoma: dose-volumetric analysis and its clinical implications | |
Rapid sequential gain of ABL1 kinase domain mutations with a complex karyotype in the progression of chronic myelogenous leukemia | |
Reference intervals for circulating angiogenic cytokines. | |
Repeated radioimmunotherapy with 131I-rituximab for patients with low-grade and aggressive relapsed or refractory B cell non-Hodgkin lymphoma | |
Retrospective comparison of bortezomib-containing regimens with vincristine-doxorubicin-dexamethasone | |
Safety and effects of prophylactic defibrotide for sinusoidal obstruction syndrome in hematopoietic stem cell transplantation | |
Selection of a mobilization regimen for multiple myeloma based on the response to induction therapy: granulocyte-colony stimulating factor (G-CSF) alone versus high-dose cyclophosphamide plus G-CSF. | |
Sequential vincristine, adriamycin, dexamethasone (VAD) followed by bortezomib, thalidomide, dexamethasone (VTD) as induction, followed by high-dose therapy with autologous stem cell transplant and consolidation therapy with bortezomib for newly dia | |
Serum and urine levels of interleukin-8 in patients with non-Hodgkin's lymphoma | |
Somatic mutation of PIK3R1 gene is rare in common human cancers | |
Somatic mutations of EGFR, ERBB2, ERBB3 and ERBB4 in juxtamembrane activating domains are rare in non-small cell lung cancers. | |
Stage IV marginal zone B-cell lymphoma--prognostic factors and the role of rituximab: Consortium for Improving Survival of Lymphoma (CISL) study | |
Statistics of hematologic malignancies in Korea: incidence, prevalence and survival rates from 1999 to 2008. | |
T-cell P/E-selectin ligand alpha(1,3)fucosylation is not required for graft-vs-host disease induction | |
T-Cell Receptor Rearrangements Determined Using Fragment Analysis in Patients With T-Acute Lymphoblastic Leukemia | |
Teaching NeuroImages: Periventricular restricted diffusion MRI in CMV ventriculitis | |
Use of lenalidomide in the management of relapsed or refractory multiple myeloma: expert recommendations in Korea | |
VEGFA and VEGFR2 genetic polymorphisms and survival in patients with diffuse large B cell lymphoma | |
면역학 |